Skip to search formSkip to main contentSkip to account menu

DU 125530

Known as: DU-125530 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Speaker 1: Francesc Artigas, Spain
Major depression is a severe and heterogeneous psychiatric disease with high, increasing prevalence and socio-economic impact.1… 
Review
2016
Review
2016
Speaker 2: Yasumasa Okamoto
s | 33 receptor antagonist DU-125530 for antidepressant treatment. Br J Pharmacol 2012; 167:1021–1034 Hughes ZA, Starr KR… 
Review
2016
Review
2016
Speaker 3: Zaida Diaz-Cabiale
s | 33 receptor antagonist DU-125530 for antidepressant treatment. Br J Pharmacol 2012; 167:1021–1034 Hughes ZA, Starr KR… 
Review
2016
Review
2016
Title: The role of serotonin in waiting for future rewards in depression
s | 33 receptor antagonist DU-125530 for antidepressant treatment. Br J Pharmacol 2012; 167:1021–1034 Hughes ZA, Starr KR… 
2012
2012
Preclinical and clinical characterization of the selective 5‐HT1A receptor antagonist DU‐125530 for antidepressant treatment
BACKGROUND AND PURPOSE The antidepressant efficacy of selective 5‐HT reuptake inhibitors (SSRI) and other 5‐HT‐enhancing drugs is… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)